Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.
Publication Title
Journal of internal medicine
Authors
Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
Ted A Gooley
Neil Bailey, Swedish Cancer Center, Seattle, WAFollow
Megumi Bailey, Swedish Medical Center, Seattle, Washington, United States.Follow
Livia Hegerova, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington.Follow
Ami Batchelder, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Heather Holdread, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Vanessa Dunleavy, Swedish Medical Center, Seattle, Washington, United States.Follow
Tyler Downey, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Jens Frisvold, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Samantha Megrath, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Krystle Pagarigan, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Jennie Szeto, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Follow
Justin Rueda, Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Follow
Adel Islam, Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Follow
Cynthia L Maree, Swedish Medical GroupFollow
Sonam Nyatsatsang, Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Follow
Sarah E Bork, Hospital Medicine, Swedish Medical Center, Seattle, WA, USA.Follow
Anne B Lipke, Swedish Medical CenterFollow
D Shane O'Mahony, Pulmonary and Critical Care, Swedish Medical Center, Seattle, WA, USA.Follow
Teresa E Wagner, Swedish Medical CenterFollow
Juan Pulido
John Mignone
Samuel Youssef
Matthew Hartman
Jason D Goldman, Division of Infectious Diseases Swedish Medical Center Seattle WA.Follow
John M Pagel, Swedish Cancer InstituteFollow
Publication Date
8-3-2020
Abstract
Severely ill COVID-19 patients have a high risk of admission to the intensive-care unit (ICU) and requirement for mechanical ventilation (MV), with in-hospital mortality reported as 18-79% globally.1-4 . Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is FDA approved for the management of CAR T-cell related Cytokine Release Syndrome (CRS) and may have utility in treatment of some COVID-19 patients. We describe the clinical characteristics and initial outcomes of a cohort of patients treated with tocilizumab at the Swedish Medical Center in Seattle, Washington.
Clinical Institute
Cancer
Specialty/Research Institute
Infectious Diseases
Specialty/Research Institute
Internal Medicine
